| Arcus Biosciences Inc (RCUS) | |||
|---|---|---|---|
| 14.28 -0.56 (-3.77%) | 04-19 12:17 | ||
| Open: | 14.77 | Pre. Close: | 14.84 |
| High: | 15.19 | Low: | 14.27 |
| Volume: | 129,528 | Market Cap: | 1,298(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 20.32  One year: 22.40 |
| Support: | Support1: 14.51 Support2: 12.07 |
| Resistance: | Resistance1: 17.40 Resistance2: 19.18 |
| Pivot: | 16.95 |
| Moving Averages: | MA(5): 15.68 MA(20): 16.96 MA(100): 17.07  MA(250): 18.03 |
| MACD: | MACD(12,26): -0.61 Signal(12,26,9): -0.32 |
| %K %D: | %K(14,3): 2.91 %D(3): 4.86 |
| RSI: | RSI(14): 33.78 |
| 52-Week: | High: 25.47 Low: 12.95 Change(%): -22.5 |
| Average Vol(K): | 3-Month: 829 10-Days: 477 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 16.064 - 16.176 | 16.176 - 16.262 |
| Low: | 14.522 - 14.666 | 14.666 - 14.777 |
| Close: | 14.642 - 14.836 | 14.836 - 14.984 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ RCUS ] has closed above bottom band by 2.5%. Bollinger Bands are 20% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Underperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: New York Stock Exchange | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | 90.86 |
| Shares Float (M) | 54.39 |
| % Held by Insiders | 41.17 |
| % Held by Institutions | 59.82 |
| Shares Short (K) | 8250 |
| Shares Short Prior Month (K) | 7680 |
| Stock Financials | |
|---|---|
| EPS | -4.150 |
| Book Value (p.s.) | 6.120 |
| Profit Margin | -262.39 |
| Operating Margin | -293.55 |
| Return on Assets (ttm) | -17.4 |
| Return on Equity (ttm) | -54.9 |
| Qtrly Rev. Growth | -8.8 |
| Gross Profit (p.s.) | |
| Sales Per Share | 1.288 |
| EBITDA (p.s.) | -3.654 |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | -306.00 |
| Levered Free Cash Flow (M) | -187.75 |
| Stock Valuation | |
|---|---|
| PE Ratio | -3.58 |
| PEG Ratio | |
| Price to Book value | 2.42 |
| Price to Sales | 11.52 |
| Price to Cash Flow | -4.41 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
